Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Most antimuscarinics contain an ester group and a basic amine group separated by a two-to-four carbon linker. Atropine, the prototype antimuscarinic, is an ester of tropic acid and tropine and serves as a reference for designing many antimuscarinic agents. This core structure resembles acetylcholine, allowing competitive binding at muscarinic receptors.

Compounds with aromatic, cyclic, or hydroxyl substitutions in the acyl portion of the ester enhance antimuscarinic effects. These ring substitutions bind outside the acetylcholine binding site because antagonists are larger than agonists, effectively blocking agonist binding and increasing receptor affinity and selectivity.

Quaternary ammonium derivatives are comparatively more potent than parent compounds with tertiary amines. The nitrogen substituent functions as a basic group essential for receptor interaction. When present as a quaternary ammonium salt, it significantly increases antagonist potency, selectivity, and overall antimuscarinic efficacy.

Antimuscarinics fall into three groups: naturally occurring alkaloids like atropine and scopolamine; semisynthetic derivatives such as homatropine and ipratropium, which differ in duration and pharmacokinetics; and synthetic compounds like tropicamide and oxybutynin, which show receptor specificity to different muscarinic receptor subtypes.

The carbon chain connecting the ester with the amine group can vary from two to four carbons, with the most potent agents having two methylene units. This optimal linker length positions the ester and amine groups for maximum receptor binding affinity and competitive antagonism at muscarinic receptors.

In nature, atropine exists as an L(-) isomer which is 100-fold more potent than the D(+) isomer. Because atropine racemizes rapidly, the racemic mixture is used therapeutically. This mixture contains both isomers but retains significant antimuscarinic activity despite the presence of the less potent D form.

Antimuscarinics compete with agonists for a common receptor, blocking acetylcholine activity at muscarinic receptors. Unlike direct acting cholinergic agonists, which activate receptors, antimuscarinics prevent agonist binding through their larger structure and strategic ring substitutions that occupy space outside the acetylcholine binding site.